Skip to main content
SpringerLink
Log in

Regulation of survival and chemoresistance by HSP90AA1 in ovarian cancer SKOV3 cells

  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

Previous researches have showed that HSP90AA is important in ovarian cancer, but the mechanism of HSP90AA is still unknown. This study aimed to investigate the role of the potential therapy target protein HSP90AA1 in ovarian cancer. The level of HSP90AA1 in ovarian cancer SKOV3 cell line was altered by RNAi and overexpression. Survival of these cell lines was investigated by tetrazolium-based assay and fluorescence-activated cell sorter (FACS). The chemosensitivity to cisplatin of the cell was also tested by FACS when HSP90AA1 was overexpressed. HSP90AA1 RNAi inhibited the proliferation of ovarian cancer SKOV3 cell line and increased the apoptosis. Furthermore, overexpression of HSP90AA1 decreased the chemosensitivity to cisplatin of SKOV3 cells and overexpression of HSP90AA1 could partially rescue the survival rate of SKOV3 cells which were treated with cisplatin. HSP90AA1 is required for the survival and proliferation of SKOV3 cells. High level of HSP90AA1 can increase chemoresistance to cisplatin of SKOV3 cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA, Schrag D, Jamison PM, Jemal A, Wu XC, Friedman C, Harlan L, Warren J, Anderson RN, Pickle LW (2005) Annual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97(19):1407–1427. doi:10.1093/jnci/dji289

    Article  PubMed  Google Scholar 

  2. Eltabbakh GH, Awtrey CS (2001) Current treatment for ovarian cancer. Expert Opin Pharmacother 2(1):109–124. doi:10.1517/14656566.2.1.109

    Article  PubMed  CAS  Google Scholar 

  3. Rebillard A, Lagadic-Gossmann D, Dimanche-Boitrel MT (2008) Cisplatin cytotoxicity: DNA and plasma membrane targets. Curr Med Chem 15(26):2656–2663

    Article  PubMed  CAS  Google Scholar 

  4. Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5(4):275–284

    Article  PubMed  CAS  Google Scholar 

  5. Tomida A, Tsuruo T (1999) Drug resistance mediated by cellular stress response to the microenvironment of solid tumors. Anticancer Drug Des 14(2):169–177

    PubMed  CAS  Google Scholar 

  6. Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR (2006) Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci 31(3):164–172

    Article  PubMed  CAS  Google Scholar 

  7. Sharp S, Workman P (2006) Inhibitors of the HSP90 molecular chaperone: current status. Adv Cancer Res 95:323–348. doi:10.1016/S0065-230X(06)95009-X

    Article  PubMed  CAS  Google Scholar 

  8. Neckers L, Ivy SP (2003) Heat shock protein 90. Curr Opin Oncol 15(6):419–424

    Article  PubMed  CAS  Google Scholar 

  9. Fortugno P, Beltrami E, Plescia J, Fontana J, Pradhan D, Marchisio PC, Sessa WC, Altieri DC (2003) Regulation of survivin function by Hsp90. Proc Natl Acad Sci USA 100(24):13791–13796. doi:10.1073/pnas.24343451002434345100

    Article  PubMed  CAS  Google Scholar 

  10. Staufer K, Stoeltzing O (2010) Implication of heat shock protein 90 (HSP90) in tumor angiogenesis: a molecular target for anti-angiogenic therapy? Curr Cancer Drug Targets 10(8):890–897

    Article  PubMed  CAS  Google Scholar 

  11. Lee CS, Kim YJ, Lee SA, Myung SC, Kim W (2012) Combined effect of Hsp90 inhibitor geldanamycin and parthenolide via reactive oxygen species-mediated apoptotic process on epithelial ovarian cancer cells. Basic Clin Pharmacol Toxicol 111(3):173–181

    PubMed  CAS  Google Scholar 

  12. Didelot C, Lanneau D, Brunet M, Joly AL, De Thonel A, Chiosis G, Garrido C (2007) Anti-cancer therapeutic approaches based on intracellular and extracellular heat shock proteins. Curr Med Chem 14(27):2839–2847

    Article  PubMed  CAS  Google Scholar 

  13. Sun L (2012) The functional study of Aha1 in the HSP90 chaperone machine. Oklahoma State University, Stillwater

    Google Scholar 

  14. Eustace BK, Sakurai T, Stewart JK, Yimlamai D, Unger C, Zehetmeier C, Lain B, Torella C, Henning SW, Beste G, Scroggins BT, Neckers L, Ilag LL, Jay DG (2004) Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat Cell Biol 6(6):507–514. doi:10.1038/ncb1131ncb1131

    Article  PubMed  CAS  Google Scholar 

  15. Matsuzaki S, Canis M, Pouly JL, Botchorishvili R, Dechelotte PJ, Mage G (2006) Differential expression of genes in eutopic and ectopic endometrium from patients with ovarian endometriosis. Fertil Steril 86(3):548–553. doi:10.1016/j.fertnstert.2006.02.093

    Article  PubMed  CAS  Google Scholar 

  16. Elpek GO, Karaveli S, Simsek T, Keles N, Aksoy NH (2003) Expression of heat-shock proteins hsp27, hsp70 and hsp90 in malignant epithelial tumour of the ovaries. APMIS 111(4):523–530

    Article  PubMed  CAS  Google Scholar 

  17. Banerji U (2009) Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res 15(1):9–14

    Article  PubMed  CAS  Google Scholar 

  18. Elpek GÖ, Karaveli Ş, Şimşek T, Keleş N, Aksoy NH (2003) Expression of heat-shock proteins hsp27, hsp70 and hsp90 in malignant epithelial tumour of the ovaries. APMIS 111(4):523–530

    Article  PubMed  CAS  Google Scholar 

  19. Vidal CI, Mintz PJ, Lu K, Ellis LM, Manenti L, Giavazzi R, Gershenson DM, Broaddus R, Liu J, Arap W (2004) An HSP90-mimic peptide revealed by fingerprinting the pool of antibodies from ovarian cancer patients. Oncogene 23(55):8859–8867

    Article  PubMed  CAS  Google Scholar 

  20. Kopper L, Peták I (2008) Apoptosis and cancer. Selected aspects of cancer progression: metastasis, apoptosis and immune response. Springer, New York, pp 103–113

    Chapter  Google Scholar 

  21. Cohen M, Dromard M, Petignat P (2010) Heat shock proteins in ovarian cancer: a potential target for therapy. Gynecol Oncol 119(1):164–166

    Article  PubMed  CAS  Google Scholar 

  22. Yang X, Wang J, Zhou Y, Wang Y, Wang S, Zhang W (2012) Hsp70 promotes chemoresistance by blocking Bax mitochondrial translocation in ovarian cancer cells. Cancer Lett 321(2):137–143

    Article  PubMed  CAS  Google Scholar 

  23. Elstrand MB, Stavnes HT, Tropé CG, Davidson B (2011) Heat shock protein 90 is a putative therapeutic target in patients with recurrent advanced-stage ovarian carcinoma with serous effusions. Hum Pathol 43(4):529–535

    Article  PubMed  Google Scholar 

  24. Fraser M, Leung B, Jahani-Asl A, Yan X, Thompson WE, Tsang BK (2003) Chemoresistance in human ovarian cancer: the role of apoptotic regulators. Reprod Biol Endocrinol 1(1):66

    Article  PubMed  Google Scholar 

  25. Sreedhar AS, Soti C, Csermely P (2004) Inhibition of Hsp90: a new strategy for inhibiting protein kinases. Biochim Biophys Acta 1697(1–2):233–242. doi:10.1016/j.bbapap.2003.11.027

    PubMed  CAS  Google Scholar 

  26. Rosenhagen MC, Soti C, Schmidt U, Wochnik GM, Hartl FU, Holsboer F, Young JC, Rein T (2003) The heat shock protein 90-targeting drug cisplatin selectively inhibits steroid receptor activation. Mol Endocrinol 17(10):1991–2001. doi:10.1210/me.2003-0141me.2003-0141

    Article  PubMed  CAS  Google Scholar 

  27. Chaudhury S, Welch TR, Blagg BSJ (2006) Hsp90 as a target for drug development. ChemMedChem 1(12):1331–1340

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Kunming General Hospital of Chengdu Military Region, No. 212 Da-Guan Road, Kunming, 650032, Yunnan Province, People’s Republic of China

    Shu-hua Chu, Yue-wang Liu, Li Zhang, Bei Liu, Li Li, Jun-zhen Shi & Li Li

Authors
  1. Shu-hua Chu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yue-wang Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Li Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bei Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Li Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jun-zhen Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Li Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Li Zhang.

Additional information

Shu-hua Chu and Yue-wang Liu contributed equally to this study.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chu, Sh., Liu, Yw., Zhang, L. et al. Regulation of survival and chemoresistance by HSP90AA1 in ovarian cancer SKOV3 cells. Mol Biol Rep 40, 1–6 (2013). https://doi.org/10.1007/s11033-012-1930-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-012-1930-3

Keywords

Search

Navigation